Corbus Pharmaceuticals (CRBP) Competitors

Corbus Pharmaceuticals (NASDAQ:CRBP) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Do analysts prefer CRBP or RGNX?

Corbus Pharmaceuticals presently has a consensus price target of $49.00, indicating a potential upside of 415.79%. REGENXBIO has a consensus price target of $28.38, indicating a potential upside of 208.42%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Corbus Pharmaceuticals is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
REGENXBIO	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Do insiders and institutionals have more ownership in CRBP or RGNX?

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 12.8% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has more risk & volatility, CRBP or RGNX?

Corbus Pharmaceuticals has a beta of 3.08, indicating that its share price is 208% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Is CRBP or RGNX more profitable?

Corbus Pharmaceuticals has a net margin of 0.00% compared to REGENXBIO's net margin of -112.70%. Corbus Pharmaceuticals' return on equity of -43.65% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-43.65%	-39.62%
REGENXBIO	-112.70%	-66.95%	-34.14%

Which has stronger valuation & earnings, CRBP or RGNX?

Corbus Pharmaceuticals has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$40.21M	-$4.76	-2.00
REGENXBIO	$83.33M	5.58	-$227.10M	-$3.44	-2.67

Does the media prefer CRBP or RGNX?

In the previous week, REGENXBIO had 12 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 16 mentions for REGENXBIO and 4 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.77 beat REGENXBIO's score of 0.79 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
REGENXBIO	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corbus Pharmaceuticals beats REGENXBIO on 10 of the 16 factors compared between the two stocks.